Oncology01
Tumor Microenvironment Modulation
Targeting stromal and immune components surrounding solid tumors to restore therapeutic susceptibility in treatment-resistant indications.
Research Portfolio
Investigations grounded in molecular evidence.
Six active programs span oncology, neurology, rare disease, and diagnostics. Each is designed in collaboration with academic principal investigators and reviewed by an independent scientific advisory board.
Neurology02
Amyloid & Tau Reduction
Small-molecule and antibody platforms designed to clear pathological protein aggregates while preserving normal cognitive scaffolding.
Neuro-immunology03
T-Cell Reprogramming
Engineering autologous immune responses to tolerate self-antigens in autoimmune neurological disease without broad immunosuppression.
Rare Disease04
Enzyme Replacement Delivery
Novel carrier systems that cross biological barriers to deliver functional enzymes to previously unreachable tissue compartments.
Diagnostics05
Multi-omic Biomarker Discovery
Integrated proteomic, transcriptomic, and metabolomic signatures that detect disease onset years before clinical presentation.
Therapeutics06
RNA-Targeted Modalities
Programmable oligonucleotide platforms that selectively modulate gene expression at single-transcript resolution.
Methodology
The principles behind every protocol.
- Pre-registration
- Every protocol, primary endpoint, and analysis plan is registered before enrollment opens.
- Independent oversight
- External data and safety monitoring boards review every interim analysis on every active trial.
- Open data
- De-identified trial-level data is shared with academic collaborators on completion.
- Patient partnership
- Patient advisory councils inform endpoint selection and consent design from protocol drafting onward.